(FM) Oncología
Departamento académico
![Foto de (FM) Oncología](/img/uploaded/1575D5546D141A10EB89AE669C8B8533.jpg)
![Foto de GlaxoSmithKline (United Kingdom)](/img/noimage_org.png)
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (15)
2024
-
A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial
Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809
-
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 187, pp. 128-138
-
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 184, pp. 168-177
2023
-
Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy
JCO clinical cancer informatics, Vol. 7, pp. e2200189
-
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
European Journal of Cancer, Vol. 189
-
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Cancer, Vol. 129, Núm. 12, pp. 1846-1855
-
Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance
Oncology and Therapy, Vol. 11, Núm. 2, pp. 245-261
2022
-
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Gynecologic Oncology, Vol. 166, Núm. 1, pp. 36-43
-
Impact of disease progression on health-related quality of life of advanced ovarian cancer patients – Pooled analysis from the PRIMA trial
Gynecologic Oncology, Vol. 166, Núm. 3, pp. 494-502
-
Niraparib treatment for patients with BRCA-mutated ovarian cancer: Review of clinical data and therapeutic context
Future Oncology, Vol. 18, Núm. 23, pp. 2505-2536
-
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Therapeutic Advances in Medical Oncology, Vol. 14
2020
-
Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
Obstetrical and Gynecological Survey
2019
-
Niraparib in patients with newly diagnosed advanced ovarian cancer
New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402
2015
-
Early prediction of disease progression in small cell lung cancer: Toward model-based personalized medicine in oncology
Cancer Research, Vol. 75, Núm. 12, pp. 2416-2425
2012
-
Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
The Lancet, Vol. 380, Núm. 9839, pp. 358-365